An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

In brief

This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred to as modules). Combinations to be studied include: 1) Module 1: AZD4635 plus durvalumab; 2) Module 2: AZD4635 plus oleclumab.

Key facts

Study ID

NCT04089553

Run by

AstraZeneca

People needed

59

Starts

2019-08-29

Expected to finish

2023-04-11

Last updated by the study team

2024-04-16

Who can join

Age: 18 and older, up to 130. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Research Site — Denver, Colorado, United States
• Research Site — Fort Myers, Florida, United States
• Research Site — St. Petersburg, Florida, United States
• Research Site — West Palm Beach, Florida, United States
• Research Site — Decatur, Illinois, United States
• Research Site — New York, New York, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Chattanooga, Tennessee, United States
• Research Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.